Doc tells investors Tofa will be a slow burn

Share this article:
Pfizer shouldn't expect its rheumatoid arthritis drug tofacitinib to just swan into first line status and blockbuster sales.

Leerink Swan analyst Seamus Fernandez wrote Wednesday that a key opinion leader – and self-proclaimed fan of Bristol-Myers Squibb's RA drug Orencia – expects the Pfizer drug will have to earn its place as a first-line treatment and will not be an immediate hit. Instead, Fernandez said the KOL, who spoke at a San Francisco investor meeting, indicated he expected tofacitinib will make its first impression as a second- or third-line treatment. This jibes with a May study by Reimbursement Intelligence which indicated payers would require patients to fail on at least two anti-TNFs before approving tofacitinib.

Fernandez wrote that the rheumatologist pointed to some hurdles, which includes her belief that the FDA may put its support behind the 5mg dose, as opposed to the 10mg dose. A lack of significant improvement at the higher dose gave an advisory committee pause when it reviewed the drug in May. Fernandez said the KOL also said tofacitinib will have to fight to differentiate itself from other in-development oral treatments, including AstraZeneca's SYK inhibitor Fos-D, and Lilly's JAK 1/2  inhibitor, among others. Fernandez added that the doctor said the key determinant will be Phase III data and safety and or/dosing profiles are set.

Tofacitinib's FDA review has been an on-and-off again situation, due to data glut. The FDA requested supplemental testing data as well as time to sort through it, which has pushed its August review date to November.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.